<DOC>
	<DOCNO>NCT02658799</DOCNO>
	<brief_summary>Non-steroidal anti-inflammatory drug ( NSAIDs ) widely use inflammation control pain relief . However , adjunct use NSAIDs avoid periodontal therapy related side effect , cyclic administration NSAIDs may reduce eliminate effect . The investigator evaluate effect cyclic diclofenac potassium regimen clinical parameter level prostaglandin E2 ( PGE2 ) interleukin-1beta ( IL-1beta ) gingival crevicular fluid ( GCF ) subject periodontitis . Forty-one subject moderate chronic periodontitis ( 33 men , 8 woman ) divide two group ( test control ) initial periodontal therapy . During 6-month , randomize , double-blind , placebo-controlled study , test ( n = 28 ) control ( n = 13 ) group administer cyclic regimen diclofenac potassium ( 50 mg , twice daily ) placebo . Clinical measurement disease severity GCF sample collection make baseline , 2 , 4 6 month . GCF level PGE2 IL1-1beta determine use EIA ELISA kit , respectively .</brief_summary>
	<brief_title>Effects Cyclic NSAID Regimen Levels GCF PGE-E2 IL-1beta</brief_title>
	<detailed_description>Study Design This study utilize randomize , control , double-blind , parallel-group design investigate 6-month effect cyclic regimen diclofenac potassium [ 50 mg , twice daily ( b.i.d ) ] clinical parameter periodontal disease level PGE2 IL-1beta GCF . After clinical radiographic examination , subject divide two group : 28 patient test group 13 patient control group . Of 28 patient test group , ten ( nine men , one woman ) smoker , eleven ( six woman , five men ) non-smokers , seven ( men ) ex-smokers . Thirteen patient control group comprise six smoker ( five men , one woman ) , five non-smokers ( four woman , one man ) two ex-smokers ( men ) . Test control group administer either diclofenac potassium ( 50 mg ) placebo gel cap ( contain inactive filler starch flour carboxymethylcellulose ) , respectively , b.i.d . meal 6 month cyclic regimen . Administration diclofenac potassium placebo undertaken baseline 2 month , drug ( diclofenac potassium placebo ) administer 2 4 month , diclofenac potassium placebo therapy reinstituted ( b.i.d . ) 4 6 month . To promote compliance , patient recall monthly . Patients group instruct oral hygiene , include tooth brush least 2 minute ( b.i.d . ) daily interdental cleaning . SRP carry recall . During screen period ( baseline well 2 , 4 6 month ) , subject underwent physical examination biochemical analysis ( blood chemistry , complete blood count , urinalyses pregnancy test ) .</detailed_description>
	<mesh_term>Periodontitis</mesh_term>
	<mesh_term>Poisoning</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Carboxymethylcellulose Sodium</mesh_term>
	<criteria>moderate chronic periodontal disease ( least two site loss clinical attachment &gt; 4mm alveolar bone loss 3050 % , judge radiography receive initial periodontal therapy , include scale root planning , well oral hygiene instruction less six week study commencement . history cardiovascular disease , renal disease , bleed upper gastrointestinal tract , gastrointestinal ulcer , asthma , hypersensitivity diclofenac NSAIDs , prosthetic joint replacement , chronic disease affect compliance receive antibiotic antibacterial agent le 6 month study commencement receive NSAIDs within 1 month , phenytoin calcium antagonist within 3 month history pregnancy , lactation , inadequate birth control</criteria>
	<gender>All</gender>
	<minimum_age>32 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>periodontitis</keyword>
	<keyword>anti-inflammatory agent</keyword>
</DOC>